163 related articles for article (PubMed ID: 12854901)
21. Immune recovery of lymphocyte subsets 6 years after autologous peripheral blood stem cell transplantation (PBSCT) for lymphoproliferative diseases. A comparison between NHL, HD and MM in group of 149 patients.
Laurenti L; Piccioni P; Piccirillo N; Sora' F; Chiusolo P; Garzia M; Reddiconto G; De Matteis S; Tarnani M; Leone G; Sica S
Leuk Lymphoma; 2004 Oct; 45(10):2063-70. PubMed ID: 15370251
[TBL] [Abstract][Full Text] [Related]
22. Prognostic impact of natural killer cell recovery on minimal residual disease after autologous stem cell transplantation in multiple myeloma.
Keruakous AR; Asch A; Aljumaily R; Zhao D; Yuen C
Transpl Immunol; 2022 Apr; 71():101544. PubMed ID: 35093506
[TBL] [Abstract][Full Text] [Related]
23. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis.
Porrata LF; Gertz MA; Litzow MR; Lacy MQ; Dispenzieri A; Inwards DJ; Ansell SM; Micallef IN; Gastineau DA; Elliott M; Hogan WJ; Hayman SR; Tefferi A; Markovic SN
Clin Cancer Res; 2005 Feb; 11(3):1210-8. PubMed ID: 15709191
[TBL] [Abstract][Full Text] [Related]
24. Lymphocyte recovery and clinical response in multiple myeloma patients receiving interferon alpha 2 beta after intensive therapy.
Millar BC; Bell JB; Powles RL
Br J Cancer; 1996 Jan; 73(2):236-40. PubMed ID: 8546912
[TBL] [Abstract][Full Text] [Related]
25. Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies.
Pavletic ZS; Joshi SS; Pirruccello SJ; Tarantolo SR; Kollath J; Reed EC; Bierman PJ; Vose JM; Warkentin PI; Gross TG; Nasrati K; Armitage JO; Kessinger A; Bishop MR
Bone Marrow Transplant; 1998 Jan; 21(1):33-41. PubMed ID: 9486492
[TBL] [Abstract][Full Text] [Related]
26. Timing of autologous stem cell transplantation from last chemotherapy affects lymphocyte collection and survival in non-Hodgkin lymphoma.
Holtan SG; Porrata LF; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Litzow MR; Gastineau DA; Markovic SN
Br J Haematol; 2006 Jun; 133(6):628-33. PubMed ID: 16704437
[TBL] [Abstract][Full Text] [Related]
27. Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications.
Steingrimsdottir H; Gruber A; Björkholm M; Svensson A; Hansson M
Haematologica; 2000 Aug; 85(8):832-8. PubMed ID: 10942930
[TBL] [Abstract][Full Text] [Related]
28. Improved Prediction of CD34+ Cell Yield before Peripheral Blood Hematopoietic Progenitor Cell Collection Using a Modified Target Value-Tailored Approach.
Sheppard D; Tay J; Palmer D; Xenocostas A; Doulaverakis C; Huebsch L; McDiarmid S; Tinmouth A; Mallick R; Martin L; Birch P; Hamelin L; Allan D; Bredeson C
Biol Blood Marrow Transplant; 2016 Apr; 22(4):763-767. PubMed ID: 26643030
[TBL] [Abstract][Full Text] [Related]
29. Immunological consequences of interleukin 12 administration after autologous stem cell transplantation.
Pelloso D; Cyran K; Timmons L; Williams BT; Robertson MJ
Clin Cancer Res; 2004 Mar; 10(6):1935-42. PubMed ID: 15041709
[TBL] [Abstract][Full Text] [Related]
30. The role of stem cell mobilization regimen on lymphocyte collection yield in patients with multiple myeloma.
Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
Cytotherapy; 2008; 10(5):507-17. PubMed ID: 18608354
[TBL] [Abstract][Full Text] [Related]
31. Factors that predict delayed platelet recovery after autologous stem cell transplantation for lymphoma or myeloma.
Nagayama T; Ashizawa M; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Mashima K; Umino K; Minakata D; Nakano H; Yamasaki R; Morita K; Kawasaki Y; Yamamoto C; Fujiwara SI; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
Ann Hematol; 2020 Dec; 99(12):2893-2901. PubMed ID: 32572522
[TBL] [Abstract][Full Text] [Related]
32. Natural killer cell numbers and activity in mobilized peripheral blood stem cell grafts: conditions for in vitro expansion.
Silva MR; Parreira A; Ascensão JL
Exp Hematol; 1995 Dec; 23(14):1676-81. PubMed ID: 8542964
[TBL] [Abstract][Full Text] [Related]
33. Peripheral blood mobilization of different lymphocyte and dendritic cell subsets with the use of intermediate doses of G-CSF in patients with non-Hodgkin's lymphoma and multiple myeloma.
Vela-Ojeda J; García-Ruiz Esparza MA; Reyes-Maldonado E; Jiménez-Zamudio L; García-Latorre E; Moreno-Lafont M; Estrada-García I; Mayani H; Montiel-Cervantes L; Tripp-Villanueva F; Ayala-Sánchez M; García-León LD; Borbolla-Escoboza JR
Ann Hematol; 2006 May; 85(5):308-14. PubMed ID: 16525786
[TBL] [Abstract][Full Text] [Related]
34. Immunologic Autograft Engineering and Survival in Non-Hodgkin Lymphoma.
Porrata LF; Burgstaler EA; Winters JL; Jacob EK; Gastineau DA; Suman VJ; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Nevala W; Markovic SN
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1017-1023. PubMed ID: 26826432
[TBL] [Abstract][Full Text] [Related]
35. Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma.
Merryman RW; Redd R; Jeter E; Wong JL; McHugh K; Reynolds C; Nazzaro M; Varden A; Brown JR; Crombie JL; Davids MS; Fisher DC; Jacobsen E; Jacobson CA; Kim AI; LaCasce AS; Ng SY; Odejide OO; Parry EM; Dahi PB; Nieto Y; Joyce RM; Chen YB; Herrera AF; Armand P; Ritz J
Transplant Cell Ther; 2022 Jan; 28(1):32.e1-32.e10. PubMed ID: 34670169
[TBL] [Abstract][Full Text] [Related]
36. Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma.
Scheid C; Pettengell R; Ghielmini M; Radford JA; Morgenstern GR; Stern PL; Crowther D
Bone Marrow Transplant; 1995 Jun; 15(6):901-6. PubMed ID: 7581089
[TBL] [Abstract][Full Text] [Related]
37. AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantation in non-Hodgkin lymphoma.
Holtan SG; Porrata LF; Micallef IN; Padley DJ; Inwards DJ; Ansell SA; Johnston PB; Gastineau DA; Markovic SN
Clin Lymphoma Myeloma; 2007 Jan; 7(4):315-8. PubMed ID: 17324341
[TBL] [Abstract][Full Text] [Related]
38. [Relationship between the absolute lymphocyte count before or after autologous hematopoietic stem cell transplantation and the prognosis in patients with non-Hodgkin's lymphoma].
Chen J; Wang JM; Zhang WP; Song XM; Qiu HY; Xu XQ; Zhou H; Chen L
Zhonghua Xue Ye Xue Za Zhi; 2010 Aug; 31(8):510-4. PubMed ID: 21122327
[TBL] [Abstract][Full Text] [Related]
39. T Cell Transcriptional Profiling and Immunophenotyping Uncover LAG3 as a Potential Significant Target of Immune Modulation in Multiple Myeloma.
Lucas F; Pennell M; Huang Y; Benson DM; Efebera YA; Chaudhry M; Hughes T; Woyach JA; Byrd JC; Zhang S; Jones D; Guan X; Burd CE; Rosko AE
Biol Blood Marrow Transplant; 2020 Jan; 26(1):7-15. PubMed ID: 31445183
[TBL] [Abstract][Full Text] [Related]
40. Early immune recovery after autologous transplantation in non-Hodgkin lymphoma patients: predictive factors and clinical significance.
Valtola J; Varmavuo V; Ropponen A; Selander T; Kuittinen O; Kuitunen H; Keskinen L; Vasala K; Nousiainen T; Mäntymaa P; Pelkonen J; Jantunen E
Leuk Lymphoma; 2016 Sep; 57(9):2025-32. PubMed ID: 26763346
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]